Cost-effectiveness of biological agents used in ulcerative colitis

Best Practice and Research: Clinical Gastroenterology

Volumn 27, Issue 6, 2013, Pages 949-960

  Lee, Jeannie K ^a,b   Tang, Derek H ^a   Mollon, Lea ^a   Armstrong, Edward P ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Biologics; Cost; Cost effectiveness; Ulcerative colitis

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOSPORIN; GOLIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; PLACEBO;

ARTICLE; BASAL CELL CARCINOMA; BIOLOGICAL THERAPY; COLON DISEASE; COLON DYSPLASIA; COLON RESECTION; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPLASIA; HEMATOLOGIC DISEASE; HOSPITALIZATION; HUMAN; INFECTION; INJECTION SITE REACTION; MAINTENANCE THERAPY; PROSTATE ADENOCARCINOMA; QUALITY ADJUSTED LIFE YEAR; REMISSION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 84887181615     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2013.09.007     Document Type: Review

References (61)

1. G.M. Eisen, and R.S. Sandler Update on the epidemiology of IBD Prog Inflmma Bowel Dis 15 1994 1 8
2. M.D. Kappelman, S.L. Rifas-Shiman, K. Kleinman, D. Ollendorf, A. Bousvaros, and R.J. Grand The prevalence and geographic distribution of crohn's disease and ulcerative colitis in the United States Clin Gastroenterol Hepatol 5 12 2007 1424 1429 [Epub 2007 Sep. 29] (Pubitemid 350181588)
3. A. Walsh, J. Mabee, and K. Trivedi Inflammatory bowel disease Prim Care Clin Office Pract 38 2011 415 432
4. G.C. Nguyen, A. Tuskey, T. Dassopoulos, M.L. Harris, and S.R. Brant Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004 Inflamm Bowel Dis 13 2007 1529 1535
5. D.T. Rubin, C.A. Siegel, S.V. Kane, D.G. Binion, R. Panaccione, and M.C. Dubinsky Impact of ulcerative colitis from patients' and physicians' perspectives: results from the UC NORMAL survey Inflamm Bowel Dis 15 2009 581 588
6. G. Moser, W. Tillinger, G. Sachs, D. Genser, T. Maier-Dobersberger, and K. Spiess Disease-related worries and concerns: a study on outpatients with inflammatory bowel disease Eur J Gastroenterol Hepatol 15 1995 104 112
7. T. Longobardi, and C.N. Bernstein Health care resource utilization in inflammatory bowel disease Clin Gastroenterol Hepatol 4 2006 731 743 (Pubitemid 43825804)
8. R.D. Cohen, and T. Thomas Economics of the use of biologics in the treatment of inflammatory bowel disease Gastroenterol Clin North Am 35 2006 867 882 (Pubitemid 44791838)
9. R.D. Cohen, A.P. Yu, E.Q. Wu, J. Xie, P.M. Mulani, and J. Chao Systematic review: the costs of ulcerative colitis in western countries Alimet Pharmacol Ther 31 2010 693 707
10. T.B. Gibson, E. Ng, R.J. Ozminkowski, S. Wang, W.N. Burton, and R.Z. Goetzel The direct and indirect cost burden of crohn's disease and ulcerative colitis J Occup Environ Med 50 2008 1261 1272
11. R. Stark, H.H. Konig, and R. Leidl Costs of inflammatory bowel disease in Germany Pharmacoeconomics 24 2006 797 814 (Pubitemid 44232107)
12. A. Bassi, S. Dodd, P. Williamson, and K. Bodger Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study Gut 53 2004 1471 1478 (Pubitemid 39265268)
13. C.N. Bernstein, N. Papineau, J. Zajaczkowski, P. Rawsthorne, G. Okruski, and J.F. Blanchard Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital Am J Gastroenterol 95 2000 677 683 (Pubitemid 30123901)
14. P.C. Heaton, N.L. Tundia, N. Schmidt, P.R. Wigle, and C.M.L. Kelton National burden of pediatric hospitalization for inflammatory bowel disease: results from the 2006 kids' inpatient database JPGN 54 2012 477 485
15. E. Hilson, S. Dybicz, H.C. Waters, B. Stuart, J. Schaneman, and O. Babbous Health care expenditures in ulcerative colitis: the perspective of a self-insured employer J Occup Environ Med 50 2008 969 977
16. S.J. Bickston, H.C. Waters, O. Babbous, B.I. Tang, and M. Rahman Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients J Manag Care Pharm 14 2008 352 362 (Pubitemid 351890850)
17. C.T. Carter, H. Leher, P. Smith, D.B. Smith, and H.C. Waters Impact of persistence with infliximab on hospitalization in ulcerative colitis Am J Manag Care 17 6 2011 385 392
18. E.V. Loftus, and W.J. Sandborn Epidemiology of inflammatory bowel disease Gastroenterol Clin North Am 31 2002 1 20 (Pubitemid 34733030)
19. T. Longobardi, P. Jacobs, and C.N. Berstein Work losses related to inflammatory bowel disease in the United States Am J Gastroenterol 98 2003 1064
20. T. Longobardi, P. Jacobs, L. Wu, and C.N. Bernstein Work losses related to inflammatory bowel disease in Canada: results from a national population health survey Am J Gastroenterol 98 2003 844 849 (Pubitemid 36576312)
21. S.R. Marri, and A.L. Buchman The education and employment status of patients with inflammatory bowel disease Inflamm Bowel Dis 11 2005 171 177 (Pubitemid 40711222)
22. S. Danese Adalimumab in ulcerative colitis: ready for prime time Dig Liver Dis 45 2013 8 13
23. V.K. Denmark, and L. Mayer Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update Expert Rev Clin Immunol 9 1 2013 77
24. P. Rutgeerts, W.J. Sandborn, B.G. Feagan, W. Reinisch, A. Olson, and J. Johanns Infliximab induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476 (Pubitemid 41770166)
25. W.J. Sandborn, P. Rutgeerts, B.G. Feagan, W. Reinisch, A. Olson, and J. Johanns Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab Gastroenterology 137 2009 1250 1260
26. G. Jarnerot, E. Hertervig, I. Friis-Liby, L. Blomquist, P. Karlen, and C. Granno Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study Gastroenterology 128 2005 1805 1811 (Pubitemid 40824691)
27. A. Gustavsson, G. Jarnerot, E. Herterviget, I. Friis-Liby, L. Blomquist, and P. Karlen Clinical trial: colectomy after rescue therapy in ulcerative colitis- 3 year follow-up of the Swedish-Danish controlled infliximab study Aliment Pharmacol Ther 32 8 2010 984 989
28. H. Fidder, F. Schnitzler, M. Ferrante, M. Noman, K. Katsanos, and S. Seqaert Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study Gut 58 2009 501 508
29. J. Ducharme, C. Pelletier, and R. Zacharias The safety of infliximab infusions in the community setting Can J Gastroenterol 24 5 2010 307 311
30. W. Reinisch, W.J. Sandborn, D.W. Hommes, G. D'Haens, S. Hanauer, and S. Schreiber Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial Gut 60 6 2011 780 787
31. W. Reinisch, W.J. Sandborn, R. Panaccione, B. Huang, P.F. Pollack, and A. Lazar 52-week clinical efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosupressants Inflamm Bowel Dis 19 8 2013 1700 1709
32. W.J. Sandborn, G. van Assche, W. Reinisch, J.F. Columbel, G. D'Haens, and D.C. Wolf Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 142 2 2012 257 265
33. L. Peyrin-Biroulet, C. Laclotte, X. Roblin, and M.A. Bigard Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study World J Gastroenterol 13 2007 2328 2332 (Pubitemid 46860734)
34. M.W. Trinder, and I.C. Lawrance Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting J Gastroenterol Hepatol 24 2009 1252 1257
35. W.J. Sandborn, J.F. Lichtenstein, S.Y. Colombel, S. Yan, B.E. Sands, and D. Eisenberg Infliximab therapy reduces hospitalizations in ulcerative colitis patients 70th Annual scientific meeting of the American college of gastroenterology, October 30-November 2, 2005, Honolulu, Hawaii, USA Am J Gastroenterol 100 2005 S287 S321 [Abstract 847]
36. B. Feagan, W.J. Sandborn, M. Yang, K. Lomax, A. Lazar, and R. Thakkar Adalimumab therapy reduces hospitalization and colectomy rates in patients with ulcerative colitis: data from controlled trials 2011 Annual scientific meeting and postgraduate course of the American college of gastroenterology (ACG) 2011
37. T. Epameinondas How expensive is inflammatory bowel disease? A critical analysis World J Gastroenterol 14 43 2008 6641 6647
38. S. Odes, H. Vardi, M. Friger, F. Wolters, M.G. Russel, and L. Riis Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation Gastroenterology 131 2006 719 728 (Pubitemid 44307060)
39. D.A. Ollendorf, and L. Lindsky Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting Am J Ther 13 2006 502 506 (Pubitemid 44813679)
40. M.P. Conolly, S.K. Nielsen, C.J. Currie, P. Marteau, C.S.J. Probert, and S.P.L. Travis An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial J Crohns Colitis 3 3 2009 168 174
41. Remicade®. In: RED BOOK online® [Internet database]. Greenwood Village, Colo: Truven Health Analytics. [Updated periodically].
42. K.T. Park, and D. Bass Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review Inflamm Bowel Dis 17 2011 1603 1609
43. Humira®. In: RED BOOK online® [Internet database]. Greenwood Village, Colo: Truven Health Analytics. [Updated periodically].
44. Y.S. Punekar, and N. Hawkins Cost-effectiveness of infliximab for the treatment of acute exacerbation of ulcerative colitis Eur J Health Econ 11 1 2010 67 76
45. J. Jones, L. Worobetz, A. Bedi, and B. Manns A cost-utility analysis of infliximab compared with surgery for the treatment of ulcerative colitis: a public payer perspective Gastroenterology 136 5 2009 A172
46. Tang DH, Harrington AR, Lee JK, Lin M, Armstrong EP. A systematic review of economic studies on biological agents used to treat Crohn's disease. Inflamm Bowel Dis Epub ahead of print 6/20/2013, http://dx.doi.org/10.1097/MIB. 0b013e3182916046.
47. S. Holubar, B. Piazik, K. Xu, D. Parambir, A. Tosteson, and C. Siegel Cost-effectiveness of infliximab versus colectomy for severe ulcerative colitis: a Markov analysis Inflamm Bowel Dis 18 2012 S57 S58
48. K. Goszczynska, W. Wrona, M. Niewada, C.M. Black, T. Fan, and P. Lobodzinski Cost-effectiveness of infliximab versus colectomy for the treatment of severe active ulcerative colitis in Poland Value in Health 16 3 2013 A213 A214
49. E. Shore The cost effectiveness of infliximab in the treatment of acute ulcerative colitis patients in Scotland Value in Health 12 7 2009 A347 A348
50. National Institute for Health and Clinical Excellence (NICE) Infliximab for acute exacerbations of ulcerative colitis 2008 Dec. 25 National Institute for Health and Clinical Excellence (NICE) London (UK) (Technology appraisal guidance; no. 163)
51. S. Bryan, L. Andronis, C. Hyde, M. Connock, A. Fry-Smith, and D. Wang Infliximab for the treatment of acute exacerbations of ulcerative colitis Health Technology Assess 14 Suppl. 1 2011 9 15
52. H.H. Tsai, Y. Punekar, J. Morris, and P. Fortun A model of the long-term cost-effectiveness of scheduled maintenance treatment with infliximab for moderate to severe ulcerative colitis Aliment Pharmacol Ther 28 10 2008 1230 1239
53. D. Tang, E. Armstrong, and J.K. Lee A cost-utility analysis of biologic treatments for moderate-to-severe crohn's disease Pharmacotherapy 32 6 2012 515 526
54. F. Xie, G. Blackhouse, N. Assasi, K. Gaebel, D. Robertson, and R. Goeree Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Cost Eff Resour Alloc 7 2009 20
55. J. Lofland, C. Gunnarsson, P. Mallow, J. Rizzo, and B. Feagan Cost-per-responder analysis of infliximab compared to adalimumab among individuals with moderate to severe ulcerative colitis Am J Gastroenterol 106 2011 S418
56. A.D. Morais, and M.L. Pereira Cost-per-number needed to treat (Nnt) analysis of infliximab compared to adalimumab in the treatment of moderate to severe ulcerative colitis in the Brazilian public health care system (Sus) Value in Health 16 3 2013 A214
57. S.H. Odes, H. Vardi, D. Greenberg, M. Friger, R.W. Stockbrugger, and C.A. O'Morain Cost-effectiveness of episodic or maintenance infliximab treatment versus standard treatment in a community-based incidence cohort of adult ulcerative colitis patients with 10-years follow-up Gastroenterology 142 5 2012 S256
58. J.F. Bridges, E. Onukwugha, and C.D. Mullins Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US Pharmacoeconomics 28 3 2010 175 184
59. V. Ung, T.W. Lee, H. Wang, K.I. Kroeker, T.X. Nguyen, and A. Ohinmaa Long-term cost-effectiveness analysis of infliximab in the management of ulcerative colitis Gastroenterology 140 5 2011 S201
60. D. Malone, J. Hurwitz, J. Lofland, B. Nejadnik, J. Vanderpoel, and H. Waters Cost-effectiveness of immunomodulators versus infliximab for adults with moderate-to-severe ulcerative colitis Inflamm Bowel Dis 17 2011 S53 S54
61. M.F. Drummond, and T.O. Jefferson Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party BMJ 313 1996 275 283 (Pubitemid 26254740)